Policy / Pricing The next FDA commissioner must be a champion for gene therapies BioSpaceThe FDA must provide consistent and predictable regulatory frameworks if the U.S.Gene Therapy PlatformRead full story pharminent June 5, 2026 (Last updated: June 5, 2026) BioSpace The FDA must provide consistent and predictable regulatory frameworks if the U.S. Gene Therapy Platform Read full story Post navigation Previous: Otsuka energizes IgA neuropathy space with new Phase 3 Voyxact dataNext: Medicare Advantage in 2026: Enrollment Update and Key Trends Related Stories Policy / Pricing Mid-cap biotechs join Trump’s latest round of drug pricing deals pharminent September 1, 2026 Policy / Pricing MFN sparks defiance from Europe’s larger nations, uncertainty among smaller ones pharminent August 27, 2026 Policy / Pricing MFN affecting Swiss medicines access, says Interpharma pharminent August 13, 2026